RDY

Dr. Reddy’s Laboratories Ltd ADR

RDY, USA

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

https://www.drreddys.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RDY
stock
RDY

(RDY) Movement as an Input in Quant Signal Sets news.stocktradersdaily.com

Read more →
RDY
stock
RDY

H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock By Investing.com Investing.com Nigeria

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$14.5863

Analyst Picks

Strong Buy

2

Buy

0

Hold

1

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

17.63

Low 50

High 10

Price to Book Ratio (P/B)

-

Very Low

0.03

Low 1

High 3

Return on Equity (ROE)

-

Very Low

4.01 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

2.65 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

6.18 %

Low 5%

High 15%

Debt to Equity

-

High

0.50

Low 1

High 0.3

Investors

* Institutions hold a combined 14.45% of the total shares of Dr. Reddy’s Laboratories Ltd ADR

1.

Robeco Institutional Asset Management BV

(1.4613%)

since

2025/06/30

2.

BlackRock Inc

(1.2538%)

since

2025/06/30

3.

Royal Bank of Canada

(1.1968%)

since

2025/06/30

4.

Renaissance Technologies Corp

(1.0828%)

since

2025/06/30

5.

Aikya Investment Management Ltd

(0.7635%)

since

2025/06/30

6.

RBC Emerging Markets Equity

(0.7195%)

since

2025/06/30

7.

RBC Emerging Markets Equity Fund F

(0.7195%)

since

2025/06/30

8.

JPMorgan Chase & Co

(0.7101%)

since

2025/06/30

9.

Dimensional Fund Advisors, Inc.

(0.6488%)

since

2025/06/30

10.

Vanguard Group Inc

(0.5977%)

since

2025/06/30

11.

Morgan Stanley - Brokerage Accounts

(0.5832%)

since

2025/06/30

12.

State Street Corp

(0.5036%)

since

2025/06/30

13.

BNP Paribas Arbitrage, SA

(0.4822%)

since

2025/06/30

14.

Robeco QI Emerging Cnsrv Eqs I €

(0.2621%)

since

2025/07/31

15.

Fisher Asset Management, LLC

(0.2426%)

since

2025/06/30

16.

Robeco QI EM Active Equities I €

(0.2405%)

since

2025/07/31

17.

Vanguard Emerging Mkts Stock Idx Inv

(0.2367%)

since

2025/07/31

18.

Vanguard Global Minimum Volatility Admr

(0.1899%)

since

2025/06/30

19.

Millennium Management LLC

(0.1837%)

since

2025/06/30

20.

DFA Emerging Markets Core Equity 2 I

(0.1635%)

since

2025/07/31

21.

Geode Capital Management, LLC

(0.1602%)

since

2025/06/30

22.

Fidelity SAI Global ex U.S. Low Vol Idx

(0.1576%)

since

2025/07/31

23.

SPDR® Portfolio Emerging Markets ETF

(0.154%)

since

2025/08/29

24.

UBS Group AG

(0.145%)

since

2025/06/30

25.

Northern Trust Corp

(0.1345%)

since

2025/06/30

26.

JPM GEM Opportunities-Composite

(0.1326%)

since

2025/06/30

27.

JPM Emerging Mkts Opps A (acc) USD

(0.1326%)

since

2025/07/31

28.

Creative Planning Inc

(0.1315%)

since

2025/06/30

29.

Avantis Emerging Markets Equity ETF

(0.1283%)

since

2025/08/30

30.

American Century Companies Inc

(0.1258%)

since

2025/06/30

31.

Bessemer Group Inc

(0.124%)

since

2025/06/30

32.

Jane Street Group LLC

(0.1201%)

since

2025/06/30

33.

Vanguard Total Intl Stock Index Inv

(0.105%)

since

2025/07/31

34.

Fisher All Foreign Equity Small Cap

(0.1002%)

since

2025/03/31

35.

JPMorgan SAR Asian - A acc - USD

(0.0664%)

since

2025/06/30

36.

Dimensional EM LrgCap Core Eq ZUSDInsAcc

(0.0664%)

since

2025/07/31

37.

DFA Emerging Markets I

(0.0608%)

since

2025/07/31

38.

RBC Emerging Markets exChina Equity Fd O

(0.0578%)

since

2025/06/30

39.

SEI Emerging Markets Equity F (SIT)

(0.0577%)

since

2025/08/31

40.

DFA Emerging Markets Value I

(0.0506%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.1685

Latest Release

Date

2025-09-30

EPS Actual

0.1972

EPS Estimate

18.31

EPS Difference

-18.1128

Surprise Percent

-98.923%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(8.5)
Defensive
Highly Defensive(8)
Dividend
Decent Dividend Payer(3.5)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(4)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Strong Net-Net(9)
Quality
High Quality(7.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.